FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955872873> ?p ?o ?g. }

• W2955872873 endingPage "4822" @default.
• W2955872873 startingPage "4822" @default.
• W2955872873 abstract "Abstract High grade serous ovarian carcinoma (HGSOC), which accounts for 70-80% of ovarian cancer deaths, is characterized by TP53 mutations and about half of these tumors present defects in homologous recombination DNA repair pathway genes. PARP inhibitors have now become FDA-approved for the treatment of recurrent and BRCA-associated ovarian cancer. Despite providing a major advance in ovarian cancer treatment in recent years, resistance to PARP inhibitors is often encountered and new treatment strategies must be devised. Oncogenic RAS and constitutively active RAS signaling regulate multiple downstream cascades to increase cell proliferation, survival, and malignant transformation. Despite the absence of RAS mutations, upregulation in the RAS pathway is prevalent in HGSOC, suggesting that these represent key, yet under-explored, inhibition targets for the treatment of ovarian cancer. Further bolstering the importance of RAS pathway inhibition are reports on cytotoxic synergistic effects for the combination of MEK and PARP inhibitors in ovarian cancer. The development of inhibitors directly targeting RAS has been hindered by the lack of suitable surfaces on the protein for small molecule binding and its high affinity for GTP binding. We developed a novel series of indene derivatives that showed highly selective growth inhibitory activity in tumor cells harboring constitutively active RAS vs. cells with low levels of active RAS. Chemical optimization led to a series of compounds that potently and selectively inhibit RAS-dependent tumor cell growth by blocking GTP binding to RAS. Here we examined the effects of RAS inhibition by two novel compounds, MCI-059 and MCI-062, in a panel of HGSOC cell lines with variable baseline levels of active RAS. We observed potent growth inhibitory activity for these novel inhibitors in most of the 15 ovarian cancer cell lines tested (IC50s ~25nM and 7nM for MCI-059 and MCI-062, respectively), with the lesser sensitivity in OV-90 cells correlating with its lowest basal levels of active RAS measured by a pull down assay using GST-RAF1-RBD/ glutathione agarose beads. Time-course experiments revealed that MCI-062 induces apoptosis beginning at 18-24 hours. Furthermore, both MCI-059 and MCI-062 inhibited: i) RAS-RAF1-RBD binding in GTPγS loaded recombinant human KRAS; ii) RAS-RAF1-RBD binding in OVCAR8 and SKOV3ip cells under normal culture growth conditions or under serum starvation followed by EGF-stimulation; iii) EGF-stimulated activation of the RAF-MEK-ERK and PI3K-AKT cascades in OVCAR-8 and SKOV3ip cells. We also confirmed that MCI-062 decreases several components of the RAS downstream signaling pathway via RPPA analysis. In summary, our results demonstrate that MCI-059 and MCI-062 inhibit HGSOC cell growth by blocking RAS-effector interactions, and support further evaluation of our novel RAS inhibitors for the treatment of ovarian cancer. Citation Format: Tyler E. Mattox, Tiffany S. Norton, Adam B. Keeton, Antonio B. Ward, Yulia Y. Maxuitenko, Kristy L. Berry, Bing Zhu, Alla Musiyenko, Elaine Gavin, Veronica Ramirez-Alcantara, Xi Chen, Jacob Valiyaveettil, Jennifer Scalici, Rodney P. Rocconi, Gary A. Piazza, Luciana Madeira da Silva. Targeting RAS and downstream signaling in high-grade serous ovarian carcinoma with novel RAS inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4822." @default.
• W2955872873 created "2019-07-12" @default.
• W2955872873 creator A5001259264 @default.
• W2955872873 creator A5003328681 @default.
• W2955872873 creator A5008171524 @default.
• W2955872873 creator A5008726864 @default.
• W2955872873 creator A5021533593 @default.
• W2955872873 creator A5025773119 @default.
• W2955872873 creator A5034358215 @default.
• W2955872873 creator A5036693985 @default.
• W2955872873 creator A5037915403 @default.
• W2955872873 creator A5038867835 @default.
• W2955872873 creator A5042371948 @default.
• W2955872873 creator A5062264366 @default.
• W2955872873 creator A5069875799 @default.
• W2955872873 creator A5071802884 @default.
• W2955872873 creator A5086841234 @default.
• W2955872873 creator A5089028589 @default.
• W2955872873 date "2019-07-01" @default.
• W2955872873 modified "2023-10-18" @default.
• W2955872873 title "Abstract 4822: Targeting RAS and downstream signaling in high-grade serous ovarian carcinoma with novel RAS inhibitors" @default.
• W2955872873 doi "https://doi.org/10.1158/1538-7445.am2019-4822" @default.
• W2955872873 hasPublicationYear "2019" @default.
• W2955872873 type Work @default.
• W2955872873 sameAs 2955872873 @default.
• W2955872873 citedByCount "0" @default.
• W2955872873 crossrefType "journal-article" @default.
• W2955872873 hasAuthorship W2955872873A5001259264 @default.
• W2955872873 hasAuthorship W2955872873A5003328681 @default.
• W2955872873 hasAuthorship W2955872873A5008171524 @default.
• W2955872873 hasAuthorship W2955872873A5008726864 @default.
• W2955872873 hasAuthorship W2955872873A5021533593 @default.
• W2955872873 hasAuthorship W2955872873A5025773119 @default.
• W2955872873 hasAuthorship W2955872873A5034358215 @default.
• W2955872873 hasAuthorship W2955872873A5036693985 @default.
• W2955872873 hasAuthorship W2955872873A5037915403 @default.
• W2955872873 hasAuthorship W2955872873A5038867835 @default.
• W2955872873 hasAuthorship W2955872873A5042371948 @default.
• W2955872873 hasAuthorship W2955872873A5062264366 @default.
• W2955872873 hasAuthorship W2955872873A5069875799 @default.
• W2955872873 hasAuthorship W2955872873A5071802884 @default.
• W2955872873 hasAuthorship W2955872873A5086841234 @default.
• W2955872873 hasAuthorship W2955872873A5089028589 @default.
• W2955872873 hasConcept C104317684 @default.
• W2955872873 hasConcept C121608353 @default.
• W2955872873 hasConcept C126322002 @default.
• W2955872873 hasConcept C127561419 @default.
• W2955872873 hasConcept C150173356 @default.
• W2955872873 hasConcept C185592680 @default.
• W2955872873 hasConcept C2780427987 @default.
• W2955872873 hasConcept C502942594 @default.
• W2955872873 hasConcept C54355233 @default.
• W2955872873 hasConcept C555283112 @default.
• W2955872873 hasConcept C62112901 @default.
• W2955872873 hasConcept C71924100 @default.
• W2955872873 hasConcept C86803240 @default.
• W2955872873 hasConceptScore W2955872873C104317684 @default.
• W2955872873 hasConceptScore W2955872873C121608353 @default.
• W2955872873 hasConceptScore W2955872873C126322002 @default.
• W2955872873 hasConceptScore W2955872873C127561419 @default.
• W2955872873 hasConceptScore W2955872873C150173356 @default.
• W2955872873 hasConceptScore W2955872873C185592680 @default.
• W2955872873 hasConceptScore W2955872873C2780427987 @default.
• W2955872873 hasConceptScore W2955872873C502942594 @default.
• W2955872873 hasConceptScore W2955872873C54355233 @default.
• W2955872873 hasConceptScore W2955872873C555283112 @default.
• W2955872873 hasConceptScore W2955872873C62112901 @default.
• W2955872873 hasConceptScore W2955872873C71924100 @default.
• W2955872873 hasConceptScore W2955872873C86803240 @default.
• W2955872873 hasIssue "13_Supplement" @default.
• W2955872873 hasLocation W29558728731 @default.
• W2955872873 hasOpenAccess W2955872873 @default.
• W2955872873 hasPrimaryLocation W29558728731 @default.
• W2955872873 hasRelatedWork W2033672302 @default.
• W2955872873 hasRelatedWork W2068614944 @default.
• W2955872873 hasRelatedWork W2139255374 @default.
• W2955872873 hasRelatedWork W2296384492 @default.
• W2955872873 hasRelatedWork W2740221126 @default.
• W2955872873 hasRelatedWork W2997955437 @default.
• W2955872873 hasRelatedWork W3012944064 @default.
• W2955872873 hasRelatedWork W3090788604 @default.
• W2955872873 hasRelatedWork W4308681997 @default.
• W2955872873 hasRelatedWork W4361823143 @default.
• W2955872873 hasVolume "79" @default.
• W2955872873 isParatext "false" @default.
• W2955872873 isRetracted "false" @default.
• W2955872873 magId "2955872873" @default.
• W2955872873 workType "article" @default.